Currently, Y-Mabs Therapeutics Inc [YMAB] is trading at $8.52, up 103.34%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The YMAB shares have gain 71.43% over the last week, with a monthly amount glided 101.90%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Y-Mabs Therapeutics Inc [NASDAQ: YMAB] stock has seen the most recent analyst activity on April 22, 2025, when BofA Securities downgraded its rating to a Underperform but kept the price target unchanged to $3 for it. Previously, Oppenheimer started tracking the stock with Outperform rating on November 18, 2024, and set its price target to $23. On August 16, 2024, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $20 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $21 on June 28, 2024. Wedbush upgraded its rating to a Outperform and raised its price target to $13 on May 10, 2023. Guggenheim downgraded its rating to Neutral for this stock on April 03, 2023. In a note dated January 27, 2023, Morgan Stanley downgraded an Underweight rating on this stock but restated the target price of $4.
This stock has fluctuated between a low of $3.55 and a high of $16.11 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Y-Mabs Therapeutics Inc [NASDAQ: YMAB] shares were valued at $8.52 at the most recent close of the market. An investor can expect a potential drop of -17.84% based on the average YMAB price forecast.
Analyzing the YMAB fundamentals
Trailing Twelve Months sales for Y-Mabs Therapeutics Inc [NASDAQ:YMAB] were 88.66M which represents 4.88% growth. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -0.35%, Pretax Profit Margin comes in at -0.32%, and Net Profit Margin reading is -0.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.31 and Total Capital is -0.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Y-Mabs Therapeutics Inc [NASDAQ:YMAB] is 4.77. Also, the Quick Ratio is 4.35, while the Cash Ratio stands at 3.18. Considering the valuation of this stock, the price to sales ratio is 4.35, the price to book ratio is 4.31.
Transactions by insiders
Recent insider trading involved Rossi Michael J, PRESIDENT & CEO, that happened on Mar 07 ’25 when 3917.0 shares were sold. CHIEF BUSINESS OFFICER, Gad Thomas completed a deal on Mar 07 ’25 to sell 10810.0 shares. Meanwhile, Officer Rajah Vignesh bought 4946.0 shares on Mar 07 ’25.
